Equity Capital Markets

Weekly Top Ten Equity Capital Markets – Jan 7, 2024

By January 7, 2024 No Comments
This weekly newsletter pulls together summaries of the top ten most-read Insights across Equity Capital Markets on Smartkarma.

Receive this weekly newsletter keeping 45k+ investors in the loop

1. APR IPO Preview

By Douglas Kim

  • APR is getting ready to complete an IPO in KOSPI in February 2024. The IPO price range is from 147,000 won to 200,000 won. 
  • According to the bankers’ valuation, the company’s valuation is expected to range from 1.1 trillion won to 1.6 trillion won post IPO. 
  • The company’s best selling product is its skin care beauty device product called Medicube Age-R. 

2. Ola Electric IPO: The Bull Case

By Arun George, Global Equity Research Ltd

  • Ola Electric (1700674D IN), the largest Indian electric two-wheel vehicles (E2W) player, is seeking US$660 million from a primary raise along with a secondary raise at a US$7-8 billion valuation. 
  • Ola is the best-selling E2W brand in India in terms of monthly E2W registrations on the VAHAN Portal of the Ministry of Road Transport and Highways.
  • The bull case rests on rising market share in a growing market, a rapid growth phase, increasing gross margin and a favourable cash conversion cycle.   

3. Hyundai Hyms IPO Preview

By Douglas Kim

  • Hyundai Hyms is getting ready to complete its IPO in KOSDAQ in January. The total IPO offering amount is 43.5 billion to 54.9 billion won. 
  • The company is offering 8.7 million shares in this IPO, of which 40% are old shares and 60% are new shares. 
  • Hyundai Hyms specializes in shipbuilding equipment. Hyundai Hyms’s main business includes shipbuilding equipment and related services. 

4. APR IPO Valuation Analysis

By Douglas Kim

  • Our base case valuation of APR is implied price of 370,809 won per share, representing an 85% upside from the high end of the bankers’ valuation range. 
  • We estimate APR to generate sales of 683.9 billion won (up 25.7% YoY) and operating profit of 114.6 billion won (up 39.5% YoY) in 2024. 
  • APR is one of the best IPOs in the Korean cosmetics sector in the past several years.

5. Hyundai Hyms IPO Valuation Analysis

By Douglas Kim

  • Our base case valuation of Hyundai Hyms is implied target price of 8,025 won per share, which is 27% higher than the high end of the IPO price range. 
  • We believe Hyundai Hyms’ valuation premium to the comps is appropriate due to much stronger operating profit growth and its strong relationships with HD Hyundai Heavy Industries.
  • Hyundai Hyms’s main business includes shipbuilding equipment and related services. The company manufactures a wide variety of items necessary for ship construction, such as ship unit blocks and piping manufacturing.

6. Pre-IPO QuantumPharm – Good Stories May Not Be Backed up by Performance

By Xinyao (Criss) Wang

  • The essential difference between QuantumPharm and InSilico in terms of business models is that InSilico is an end-to-end generative AI-driven biotech but QuantumPharm is more of a platform-based service provider.
  • It’s difficult for QuantumPharm to achieve significant increase in revenue scale in short time,because the service fee amount is usually not large, and it takes time to accumulate order volume.
  • If there is no substantial performance contribution, these good stories would not bring about a sustained leap in valuation. QuantumPharm’s valuation in last funding round before IPO is too expensive. 

7. MIXUE Group IPO: The Investment Case

By Arun George, Global Equity Research Ltd

  • Mixue Group (MIX HK), a world-leading freshly made drinks company, filed for an HKEx IPO to raise US$0.5-1.0 billion. 
  • Mixue is China’s largest and the world’s second-largest freshly made drinks company, in terms of both the number of stores and cups sold in 9M23, according to CIC.
  • The investment case rests on a strong brand, leading market share, high revenue growth, robust cost control, stable profitability and cash generation. 

8. Weekly Deals Digest (07 Jan) – Ola Electric, Mixue, Aoki Super, Hollysys, Weiqiao Textile, Vinda

By Arun George, Global Equity Research Ltd

9. J&T Global Express FY23 Earnings Preview | Revenue Growth & Margin | China, SE Asia, ‘Other’

By Daniel Hellberg, Tracking Traffic

  • In this insight we preview J&T’s maiden earnings report as a listed company
  • We focus on revenue growth & margin trends in the China & SE Asia businesses
  • We fear slowing organic growth & margin deterioration could spook investors

10. Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation

By Ke Yan, CFA, FRM, Aequitas Research

  • Cloudbreak Pharma, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.
  • In this note, we examine the company’s core products, namely CBT-001 and CBT-009, for pterygium and juvenile myopia respectively.
  • We are seeing a lack of convincing sustainable innovation from the company. Pre-IPO investors and management are mediocre.